The role of bisphosphonates in the management of prostate cancer.

Current Oncology Reports
F Saad

Abstract

Current therapies have extended the survival of patients with prostate cancer. However, these patients often develop skeletal morbidity from disease- and treatment-related effects that undermine skeletal integrity throughout the course of the disease. Low bone mineral density (BMD) is prevalent in patients with early-stage prostate cancer, and androgen-deprivation therapy by either pharmaceutical agent (including hormonal) or surgical castration causes significant decreases in BMD. Fractures can result in a loss of independence and have been associated with shorter survival in patients with prostate cancer. Zoledronic acid is the only bisphosphonate that has demonstrated objective and long-term benefits in reducing skeletal morbidity in patients with bone metastases due to prostate cancer, and it has produced long-term reductions in pain levels compared with placebo in this setting. Therefore, bisphosphonates, particularly zoledronic acid, may provide important benefits for preserving bone health during the course of prostate cancer progression.

References

Jan 1, 1992·International Urology and Nephrology·I ElomaaJ Seppänen
Jan 1, 1995·Journal of Neuro-oncology·J L OsbornD L Trump
Jun 15, 1996·The Journal of Clinical Investigation·G A Rodan, H A Fleisch
Dec 22, 1999·The Journal of Urology·H W DaniellP T Stratte
Sep 29, 2001·The New England Journal of Medicine·M R SmithJ S Finkelstein
Jun 22, 2002·The Cochrane Database of Systematic Reviews·R Wong, P J Wiffen
Jun 28, 2002·Cancer Metastasis Reviews·E T KellerR S Taichman
Oct 3, 2002·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
Nov 1, 2002·Current Opinion in Oncology·Jonathan R Green
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D S ErnstW Parulekar
Sep 4, 2003·Journal of the National Cancer Institute·David P DearnaleyUNKNOWN Mrc Pr05 Collaborators
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallMildred Ortu Kowalski
Jun 3, 2004·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
Jan 6, 2005·Journal of the National Cancer Institute·Janet E BrownRobert E Coleman
Jan 14, 2005·The New England Journal of Medicine·Vahakn B ShahinianJames S Goodwin
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 1, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K P WeinfurtK A Schulman
Jul 8, 2005·Cancer Chemotherapy and Pharmacology·Gianfilippo BertelliMarco Merlano
Sep 29, 2005·The Journal of Clinical Endocrinology and Metabolism·Susan L GreenspanNeil M Resnick
Nov 11, 2005·Journal of the National Comprehensive Cancer Network : JNCCN·David Ettinger, Bruce Johnson
Jul 25, 2006·Hematology/oncology Clinics of North America·Fred Saad

❮ Previous
Next ❯

Citations

Jul 3, 2021·International Journal of Molecular Sciences·Zintle Mbese, Blessing A Aderibigbe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.